{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 464214518
| image = Pristinamycin IA.png
| image2 = Streptogramin A.svg
<!--Combo data-->
| type = combo
| component1 = Pristinamycin IA
| class1 = [[antibiotic]]
| component2 = Pristinamycin IIA
| class2 = [[antibiotic]]
<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|international|pristinamycin}}
| MedlinePlus = a603007
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status =  
| routes_of_administration =
<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 270076-60-3
| ATCvet =  
| ATC_prefix = J01
| ATC_suffix = FG01
| PubChem = 11979535
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 10152812
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1256399
<!--Chemical data-->
}}

'''Pristinamycin''' ([[International Nonproprietary Name|INN]]), also spelled '''pristinamycine''', is an [[antibiotic]] used primarily in the treatment of [[Staphylococcus|staphylococcal]] infections, and to a lesser extent [[Streptococcus|streptococcal]] infections. It is a [[streptogramin]] group antibiotic, similar to [[virginiamycin]], derived from the bacterium ''[[Streptomyces|Streptomyces pristinaespiralis]]''. It is marketed in Europe by [[Sanofi-Aventis]] under the trade name '''Pyostacine'''.

Pristinamycin is a mixture of two components that have a synergistic antibacterial action. [[Pristinamycin IA]] is a [[macrolide]], and results in pristinamycin's having a similar spectrum of action to [[erythromycin]]. [[Pristinamycin IIA]] (streptogramin A) is a [[depsipeptide]].<ref name="Hamilton-Miller1991">{{cite journal | author = Hamilton-Miller J | title = From foreign pharmacopoeias: 'new' antibiotics from old? | journal = J Antimicrob Chemother | volume = 27 | issue = 6 | pages = 702–5 | year = 1991 | pmid = 1938680 | doi = 10.1093/jac/27.6.702}}</ref> PI and PII are coproduced by ''S. pristinaespiralis'' in a ratio of 30:70. Each compound binds to the bacterial 50 S ribosomal subunit and inhibits the elongation process of the protein synthesis, thereby exhibiting only a moderate bacteriostatic activity. However, the combination of both substances acts synergistically and  leads to a potent bactericidal activity that can reach up to 100 times that of the separate components.

The pristinamycin biosynthetic gene cluster is the largest antibiotic supercluster known so far, with a size of ~210 kb, wherein the PI and PII biosynthetic genes are not clustered individually but are scattered across the complete sequence region.<ref>Mast Y, Weber T, Gölz M, Ort-Winklbauer R, Gondran A, Wohlleben W, Schinko E (2010) Characterization of the ‘pristinamycin supercluster’ of Streptomyces pristinaespiralis. Microbial Biotechnology. {{doi|10.1111/j.1751-7915.2010.00213.x}}</ref> Furthermore, this biosynthetic gene region is interrupted by a cryptic type II PKS gene cluster.

==Clinical use==
Despite the macrolide component, it is effective against erythromycin-resistant staphylococci and strepcococci.<ref name="Weber2001">{{cite journal | author = Weber P | title = [Streptococcus pneumoniae: lack of emergence of pristinamycin resistance] | journal = Pathol Biol (Paris) | volume = 49 | issue = 10 | pages = 840–5 | year = 2001 | pmid = 11776696 | doi = 10.1016/S0369-8114(01)00255-3}}</ref><ref name="Leclercq2003">{{cite journal |vauthors=Leclercq R, Soussy C, Weber P, Moniot-Ville N, Dib C | title = [In vitro activity of the pristinamycin against the isolated staphylococci in the french hospitals in 1999-2000] | journal = Pathol Biol (Paris) | volume = 51 | issue = 7 | pages = 400–4 | year = 2003 | pmid = 12948760 | doi = 10.1016/S0369-8114(03)00054-3}}</ref>  It is active against [[Methicillin-resistant Staphylococcus aureus|methicillin-resistant ''Staphylococcus aureus'']] (MRSA). Its usefulness for severe infections, however, may be limited by the lack of an [[intravenous]] formulation owing to its poor solubility.<ref name="Martindale34">{{cite book | editor= Edited by Sean C. Sweetman | title=[[Martindale: The complete drug reference]] | edition=34th | date=November 30, 2004 | publisher=Pharmaceutical Press | location=London | isbn= 0-85369-550-4}}</ref> Nevertheless, it is sometimes used as an alternative to [[rifampicin]]+[[fusidic acid]] or [[linezolid]] for the treatment of MRSA.

The lack of an intravenous formulation led to the development of the pristinamycin-derivative [[quinupristin/dalfopristin]] (i.e., [[Synercid]]), which may be administered intravenously for more severe MRSA infections.

== See also ==
* [[Methicillin-resistant Staphylococcus aureus|Methicillin-resistant ''Staphylococcus aureus'']] (MRSA)
* [[Quinupristin/dalfopristin]]

== Footnotes ==
{{reflist}}

{{Macrolides, lincosamides and streptogramins}}

[[Category:Antibiotics]]
[[Category:Combination antibiotics]]
[[Category:Depsipeptides]]
[[Category:Cyclic peptides]]